



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/553,139
Filing Date	October 14, 2005
First Named Inventor	Jonathan M. COHEN
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	36119.232US3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2004/0204372 A1	10-14-2004	Cohen et al.	
	AB*	US-4,477,452	10-16-1984	Haeger	
	AC*	US-4,534,977	08-13-1985	Haeger	
	AD*	US-4,562,073	12-31-1985	Micetich et al.	
	AE*	US-6,207,661-B1	04-27-2001	Thompson et al.	
	AF*	US-6,503,881-A1	01-07-2003	Krieger et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Footnote
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-00/50035-A2	08-31-2000	Baxter International Inc.		
	BB	WO-03/088914-A2	10-30-2003	The University of Iowa Research Foundation		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	MATHEW et al., "Stability of piperacillin sodium in the presence of tazobactam sodium in 5% dextrose and normal saline injections," Journal of Clinical Pharmacy and Therapeutics, 19: 397-399 (1994)	
	CB	PARK et al., "Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions," Am J Health-Syst Pharm, 52: 2022-2024 (1995)	
	CC	Remington's Pharmaceutical Sciences, 18th edition, A.R. Gennaro, ed., Mack Publishing, 1990, pages 1565-1569.	
	CD	ROWE et al., "Edetic Acid", Handbook of Pharmaceutical Excipients, third edition, Pharmaceutical Press, Washington: XP-002291434 (2000) pp.191-194.	
	CE	"Sodium Citrate Dihydrate", Handbook of Pharmaceutical Excipients, 3rd edition, Arthur H. Kibbe, Ph.D., ed., pages 482-484 (2000)	
	CF	The United States Pharmacopeia, National Formulary, USP26, NF 21, Jan. 1, 2003, pp. 1483-1485.	
	CG	The United States Pharmacopeia, National Formulary, USP26, NF 21, Jan. 1, 2003, pp. 2189-2196.	
	CH	The United States Pharmacopeia, National Formulary (1) Supplement, Apr. 1, 2003, pp. 2990-2991.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

5495661

5495661

US1DOCS 5495661

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.K./

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/553,139
				Filing Date	October 14, 2005
				First Named Inventor	Jonathan M. COHEN
				Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	2	Attorney Docket Number	36119.232US3

	CI	VAN DER BERG et al., "Effect of Freezing on the pH and Composition of Sodium and Potassium Phosphate Solutions: the Reciprocal System $\text{KH}_2\text{PO}_4\text{-Na}_2\text{HPO}_4\text{-H}_2\text{O}$ " Archives of Biochemistry and Biophysics, 81: 319-325 (1959)	
	CJ	Zosyn® Package Insert, no date available.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jody Karol/	Date Considered	04/01/2008
-----------------------	--------------	--------------------	------------

5495661

US10005 5495661v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.K./